Netarsudil vs Timolol for Glaucoma

This trial examines two eye drop medications, netarsudil (Rhopressa) and timolol maleate, to determine which better protects nerve cells in people with open-angle glaucoma. Both medications lower eye pressure, but researchers aim to discover if Rhopressa more effectively prevents the loss of crucial sight-carrying nerve cells. Participants will use each medication for six months and undergo several eye exams and tests to monitor changes. This trial suits individuals diagnosed with open-angle glaucoma, who have had an eye exam in the past year, and can see reasonably well with glasses or contacts. As a Phase 4 trial, this research aims to understand how these FDA-approved treatments benefit a broader range of patients.

Research has shown that both netarsudil (Rhopressa) and timolol are generally safe for treating glaucoma, a condition that increases eye pressure.

For netarsudil, studies have found that the most common side effect is redness of the eye, known as conjunctival hyperemia, occurring in about 53% of users. Despite this, netarsudil remains safe and effective in lowering eye pressure, which is crucial for glaucoma patients.

Timolol is also well-tolerated. Some studies reported that about 7% of patients experienced mild eye discomfort. Timolol may slightly lower heart rate in some individuals, but this effect is usually mild. Overall, many people with glaucoma have safely used both medications.

Unlike the standard treatments for glaucoma, such as Timolol Maleate, which primarily reduce intraocular pressure by decreasing fluid production in the eye, Netarsudil (Rhopressa) offers a unique approach. Netarsudil works by increasing the eye's fluid outflow through a pathway called the trabecular meshwork, which is novel compared to traditional therapies. This distinct mechanism of action could provide an alternative for patients who do not respond adequately to current treatments, offering hope for better pressure control in the eye and potentially improved outcomes. Researchers are excited because Netarsudil's unique pathway might address unmet needs in glaucoma management, offering a new option for patients with this condition.

Research has shown that netarsudil (Rhopressa), which participants in this trial may receive first or second, effectively lowers eye pressure in people with glaucoma. Specifically, studies found that 48% of eyes experienced at least a 20% drop in eye pressure after one month, with this effect lasting for six months. Timolol, another treatment option in this trial, also reduces eye pressure and is commonly used for treating open-angle glaucoma. Most people tolerate it well. Both treatments are approved for lowering eye pressure, which is crucial for protecting the nerve cells in the eye.⁶⁷⁸⁹¹⁰